ID   HCC1937 BL
AC   CVCL_3281
SY   HCC-1937BL; HCC1937-BL; HCC1937BL; Hamon Cancer Center 1937 BL
DR   CLO; CLO_0003646
DR   ATCC; CRL-2337
DR   BioSample; SAMN03471821
DR   Cell_Model_Passport; SIDM00873
DR   DepMap; ACH-002375
DR   DSMZ; ACC-891
DR   DSMZCellDive; ACC-891
DR   KCLB; 9S1937BL
DR   Wikidata; Q28872486
RX   PubMed=9699648;
RX   PubMed=9833771;
RX   PubMed=20164919;
RX   PubMed=22032724;
RX   PubMed=25960936;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Population: Caucasian.
CC   Doubling time: ~48 hours (DSMZ=ACC-891).
CC   HLA typing: A*23:01,24:02; B*40:01,07:02; C*03:04,07:02; DQA1*04:01,01:02; DQB1*06:02,04:02; DRB1*08:01,15:01 (PubMed=25960936).
CC   Sequence variation: Mutation; HGNC; 1100; BRCA1; Simple; p.Gln1756Profs*74 (c.5266dupC) (5382insC); ClinVar=VCV000017677; Zygosity=Heterozygous; Note=The breast carcinoma cell line HCC1937 (Cellosaurus=CVCL_0290) is homozygous for the same mutation (PubMed=9699648; PubMed=22032724).
CC   Transformant: NCBI_TaxID; 10376; Epstein-Barr virus (EBV).
CC   Omics: Deep exome analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Misspelling: HCC2337; PubMed=22032724; Note=Probably due to confusion with ATCC catalog number (CRL-2337).
CC   Misspelling: HCC-2337; PubMed=25960936; Note=Probably due to confusion with ATCC catalog number (CRL-2337).
CC   Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178.
CC   Cell type: B-cell; CL=CL_0000236.
ST   Source(s): ATCC=CRL-2337; DSMZ=ACC-891
ST   Amelogenin: X
ST   CSF1PO: 11,12
ST   D13S317: 13 (ATCC=CRL-2337)
ST   D13S317: 13,14 (DSMZ=ACC-891)
ST   D16S539: 13 (DSMZ=ACC-891)
ST   D16S539: 13,14 (ATCC=CRL-2337)
ST   D18S51: 12,15
ST   D19S433: 14,15
ST   D21S11: 28,32.2
ST   D2S1338: 20,25
ST   D3S1358: 17,18
ST   D5S818: 12
ST   D7S820: 9,10
ST   D8S1179: 12,13
ST   FGA: 20,22
ST   Penta D: 9,11
ST   Penta E: 7,13
ST   TH01: 6
ST   TPOX: 8,11
ST   vWA: 16,17
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_0290 ! HCC1937
SX   Female
AG   24Y
CA   Transformed cell line
DT   Created: 04-04-12; Last updated: 02-05-24; Version: 27
//
RX   PubMed=9699648;
RA   Tomlinson G.E., Chen T.T.-L., Stastny V.A., Virmani A.K., Spillman M.A.,
RA   Tonk V., Blum J.L., Schneider N.R., Wistuba I.I., Shay J.W.,
RA   Minna J.D., Gazdar A.F.;
RT   "Characterization of a breast cancer cell line derived from a
RT   germ-line BRCA1 mutation carrier.";
RL   Cancer Res. 58:3237-3242(1998).
//
RX   PubMed=9833771; DOI=10.1002/(SICI)1097-0215(19981209)78:6<766::AID-IJC15>3.0.CO;2-L;
RA   Gazdar A.F., Kurvari V., Virmani A.K., Gollahon L.S., Sakaguchi M.,
RA   Westerfield M., Kodagoda D.R., Stasny V., Cunningham H.T., Wistuba I.I.,
RA   Tomlinson G.E., Tonk V., Ashfaq R., Leitch A.M., Minna J.D., Shay J.W.;
RT   "Characterization of paired tumor and non-tumor cell lines established
RT   from patients with breast cancer.";
RL   Int. J. Cancer 78:766-774(1998).
//
RX   PubMed=20164919; DOI=10.1038/nature08768; PMCID=PMC3145113;
RA   Bignell G.R., Greenman C.D., Davies H.R., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
//
RX   PubMed=22032724; DOI=10.1186/1755-8794-4-75; PMCID=PMC3227591;
RA   Ha K.C.H., Lalonde E., Li L.-L., Cavallone L., Natrajan R.,
RA   Lambros M.B., Mitsopoulos C., Hakas J., Kozarewa I., Fenwick K.,
RA   Lord C.J., Ashworth A., Vincent-Salomon A., Basik M., Reis-Filho J.S.,
RA   Majewski J., Foulkes W.D.;
RT   "Identification of gene fusion transcripts by transcriptome sequencing
RT   in BRCA1-mutated breast cancers and cell lines.";
RL   BMC Med. Genomics 4:75.1-75.13(2011).
//
RX   PubMed=25960936; DOI=10.4161/21624011.2014.954893; PMCID=PMC4355981;
RA   Boegel S., Lower M., Bukur T., Sahin U., Castle J.C.;
RT   "A catalog of HLA type, HLA expression, and neo-epitope candidates in
RT   human cancer cell lines.";
RL   OncoImmunology 3:e954893.1-e954893.12(2014).
//